Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on June 8, 2005. The filing reports on actions taken at the company's 2005 annual meeting of stockholders regarding the approval of director compensation and amendments to the 2004 Stock Incentive Plan.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and compensation agreements.
Material Changes
The primary material change reported is the stockholder approval of a new compensation structure for the Board of Directors, effective immediately following the June 8, 2005 annual meeting. Key changes include:
- Cash Compensation: Non-employee directors will receive $5,000 per fiscal quarter. Additional annual fees of $5,000 are approved for committee chairmen, with an extra $10,000 annual fee for the Audit Committee chairman.
- Equity Compensation: The 2004 Stock Incentive Plan was amended to grant nonstatutory stock options to non-employee directors. New directors receive options for 25,000 shares (vesting over three years), while continuing directors receive options for 10,000 shares annually (vesting in one year). The Audit Committee chairman receives an additional 10,000 shares annually.
- Immediate Grants: On June 8, 2005, options to purchase 10,000 shares each were granted to six directors (Peter Barrett, John E. Berriman, John K. Clarke, Paul R. Schimmel, Phillip A. Sharp, and Kevin P. Starr) at an exercise price of $7.08 per share. Kevin P. Starr received an additional 10,000 shares as Audit Committee chairman.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, future outlook, management commentary on business strategy, or specific risk factors. The only contingency noted is that the vesting of stock options is subject to the individual's continued service as a director.
Investor Verification Checklist
- Verify the total number of shares authorized under the amended 2004 Stock Incentive Plan to ensure sufficient shares remain for future grants.
- Confirm the impact of the new director compensation structure on the company's future operating expenses and cash burn rate.
- Review the specific vesting schedules and exercise terms for the options granted on June 8, 2005, as detailed in Exhibit 10.2.
- Check subsequent filings for any changes to the Board composition that would trigger new option grants under the amended plan.